Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib

    January 2023 in “ Cutis ”
    Ivie Obeime
    Image of study
    TLDR The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
    The paper discusses the impact of the first FDA-approved medication for alopecia areata (AA), baricitinib, a Janus kinase (JAK) inhibitor. AA is an autoimmune genetic disease causing relapsing and remitting nonscarring hair loss, with patients reporting lower health-related quality of life scores compared to other skin conditions. The paper highlights the need for real-world outcomes and considerations for different races and ethnicities. The two phase 3 trials for baricitinib included Black and Latino patients, but not in a representative way. Recent studies suggest an increased prevalence of AA in Black patients in the US, raising concerns about access to care and treatment. The phase 3 trials for baricitinib, BRAVE-AA1 (N=654) and BRAVE-AA2 (N=546), showed 33% of patients achieved 80% or more scalp coverage at 36 weeks. However, of the total 1200 patients, only 98 identified as Black, indicating a need for more diversified study participants. Other treatments, such as ritlecitinib, brepocitinib, and deuruxolitinib, are also on the horizon.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

      community What else is good. Besides the big 3.

      in Chat  34 upvotes 2 months ago
      Key treatments for hair preservation include minoxidil, finasteride/dutasteride, and microneedling, with additional options like specific shampoos, oils, biotin, zinc, tretinoin, clascoterone, and low-level laser therapy. Maintaining a healthy lifestyle, reducing stress, and addressing nutrient deficiencies can also support hair health.

      community I am a dermatologist with a clinical interest in alopecia. AMA

      in Will treatment work for me? 2 years ago
      In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.

      community Olumiant active ingredient Baricitinib

      in Research/Science  1 upvotes 2 years ago
      The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.

    Related Research

    1 / 1 results